Pre-Close Trading Update

RNS Number : 8331S

Alliance Pharma PLC

13 July 2015

 



13 July 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Pre-Close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2015.

The Group continues to perform well and in line with management's expectations, with sales of approximately £22.8m (H1 2014: £21.4m) in the first half of the year.

Our growth products continue to deliver, with Hydromol™ generating sales of £3.3m in the period, 10% higher than in the same period in the prior year despite the additional PPRS rebate deduction.

MacuShield™, acquired in February this year, is performing in line with expectations and we look forward to the return of ImmuCyst in the second half of the year, although volumes remain uncertain as Sanofi's facility ramps up production.

Alliance continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year.

The Company's interim results for the six months ended 30 June 2015 are scheduled to be released on 9 September 2015.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

TSTSFUSIDFISELW